Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes: a Prospective, Open-label, Non-inferiority Randomized Trial

NCT05457933 is registered in ClinicalTrials.gov with Medanta, The Medicity, India as lead sponsor.

NCT NCT05457933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05457933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes: a Prospective, Open-label, Non-inferiority Randomized Trial
Lead sponsor
Medanta, The Medicity, India
Phase
Phase 4
Overall status
Completed
Start date
July 29, 2022
Completion date
January 14, 2023
Enrollment
250 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery disease, type2diabetes